Personalized cancer vaccines

Current State

Personalized cancer vaccines (PCVs) are at the forefront of cancer immunotherapy, designed to target patient-specific tumor neoantigens. Recent advancements, particularly in mRNA-based vaccines, have shown promising results in clinical trials for difficult-to-treat cancers. For instance, individualized neoantigen vaccines have been shown to stimulate T cells and prime long-lived CD8+ T cells in pancreatic ductal adenocarcinoma (PDAC) patients, even in a disease with low mutational burden. Similarly, neoantigen vaccines have generated anti-tumor immunity in renal cell carcinoma (RCC), demonstrating the ability to target cancer driver mutations and induce immune recognition of the tumor. The development of computational tools like pVACtools has significantly improved the identification and visualization of cancer neoantigens, a critical step for vaccine design. Furthermore, innovative delivery systems, such as lipid nanoparticle (LNP)-mediated lymph node-targeting mRNA vaccines and lipopolyplex (LPP)-formulated mRNA vaccines, are enhancing the efficiency and robustness of T cell responses.

Strongest Evidence

Clinical trials provide the strongest evidence for PCVs. A phase I trial in PDAC demonstrated that an individualized mRNA neoantigen vaccine (autogene cevumeran), administered after surgery and atezolizumab, stimulated T cells and primed long-lived CD8+ T cells, with a median follow-up of 3.2 years. Another phase I trial in RCC showed that a neoantigen-targeting PCV generated circulating immune responses against predicted neoantigens, leading to immune recognition of the patient's tumor. Beyond mRNA, other platforms are emerging, including circular RNA-based vaccines for hepatocellular carcinoma (HCC) and personalized vaccines utilizing tumor extracellular vesicles or surgically removed tumor material, which aim to overcome limitations of linear mRNA and enhance immunogenicity.

Unresolved Uncertainties

Despite progress, several uncertainties persist. Optimizing neoantigen prediction accuracy remains a challenge, as suboptimal prediction can compromise therapeutic efficacy. The long-term clinical efficacy and durability of immune responses across a broader spectrum of tumor types and patient populations need further investigation. Enhancing delivery efficiency and ensuring robust, sustained immune responses are ongoing areas of research. The integration of PCVs with other immunotherapies and standard treatments also requires further exploration to maximize clinical benefit. Additionally, the scalability and cost-effectiveness of personalized manufacturing processes are practical considerations.

Why the Topic Matters

Personalized cancer vaccines represent a paradigm shift in cancer treatment, moving towards highly individualized therapies that harness the patient's own immune system to specifically target their unique tumor. This approach holds immense potential for patients with limited treatment options, particularly those with cancers characterized by low mutational burdens or high recurrence rates. By eliciting specific and durable anti-tumor immune responses, PCVs could significantly improve patient outcomes, reduce recurrence, and offer a less toxic alternative or complement to conventional therapies. The ongoing advancements in genomics, immunology, and material science continue to push the boundaries of what is possible in cancer immunotherapy.

Points of Agreement

• Personalized cancer vaccines (PCVs) can generate robust, neoantigen-specific T-cell responses against predicted neoantigens (Braun et al., 2025; Rojas et al., 2023; Sethna et al., 2025).
• mRNA-lipoplex vaccines are effective in priming long-lived CD8+ T cells, particularly in cancers like pancreatic ductal adenocarcinoma (PDAC) (Rojas et al., 2023; Sethna et al., 2025).
• PCVs show clinical activity and can induce immune recognition of a patient's tumor, even in tumors with low mutational burden (Braun et al., 2025).
• Computational tools like pVACtools are crucial for identifying and visualizing cancer neoantigens, supporting vaccine design (Hundal et al., 2020).
• Targeted delivery of mRNA to lymph nodes (LNs) using lipid nanoparticles (LNPs) can enhance immune responses and reduce side effects (Chen et al., 2022).

Active Disagreements

• The optimal formulation and delivery method for mRNA vaccines are still being explored, with various approaches like lipopolyplexes (Fan et al., 2024), circular RNA (Wang et al., 2024), and tumor extracellular vesicles (Han et al., 2024) being investigated to improve stability, expression persistence, and immunogenicity.
• While some studies highlight the potential of PCVs in preventing postoperative recurrence (Cai et al., 2021; Wang et al., 2018; Ye et al., 2019), the most effective strategies for integrating vaccines with other postoperative therapies (e.g., chemotherapy, checkpoint blockade) are still under active investigation.

Uncertain Claims

• The full extent to which PCV-induced immune responses can target cancer driver mutations and translate into sustained clinical benefit across all cancer types is still being elucidated (Braun et al., 2025).
• The long-term efficacy and durability of immune responses generated by PCVs, especially in preventing recurrence in high-risk patients, require further extended follow-up studies (Cai et al., 2021; Sethna et al., 2025).

Evidence Gaps

• More extensive clinical trials are needed to validate the efficacy of PCVs in a broader range of cancer types and stages, beyond PDAC, RCC, and HCC (Sahin & Türeci, 2018).
• Further research is required to optimize neoantigen prediction accuracy and improve delivery efficiency to enhance the in vivo therapeutic efficacy of mRNA vaccines (Fan et al., 2024).
• There is a need for standardized protocols and biomarkers to predict patient response to PCVs and to guide personalized treatment strategies.
• Comparative studies are needed to evaluate the relative advantages and disadvantages of different vaccine platforms (mRNA, viral vector, peptide-based) in various clinical settings.

Personalized cancer vaccines (PCVs) are designed to target patient-specific tumor mutations (neoantigens) and have demonstrated the ability to stimulate anti-tumor immune responses. The evidence supporting this claim is strong, particularly with mRNA-based platforms.

Claim 1: Personalized RNA neoantigen vaccines stimulate T cells and can generate long-lived CD8+ T cells.

• Supporting Evidence: Studies in pancreatic ductal adenocarcinoma (PDAC) have shown that individualized mRNA neoantigen vaccines (e.g., autogene cevumeran) stimulate T cells (Rojas et al., 2023). Extended follow-up from a Phase 1 trial further indicates that these mRNA-lipoplex vaccines can prime long-lived CD8+ T cells specific for tumor antigens in PDAC patients (Sethna et al., 2025). This suggests a durable immune response.
• Limitations: While T cell stimulation is observed, the direct correlation with significant clinical benefit across all patients still requires further investigation in larger trials.
• Evidence Strength: Strong.

Claim 2: PCVs can generate anti-tumor immunity and lead to immune recognition of a patient’s tumor, even in cancers with low mutational burden.

• Supporting Evidence: A Phase 1 trial in renal cell carcinoma (RCC), a tumor type often characterized by a low mutational burden, demonstrated that a neoantigen vaccine generated circulating immune responses against predicted neoantigens and led to immune recognition of the patient's tumor (Braun et al., 2025). This indicates that PCVs can be effective beyond highly mutated cancers.
• Limitations: The extent of clinical activity and long-term outcomes in RCC patients are still being evaluated.
• Evidence Strength: Moderate to Strong.

Claim 3: Advanced delivery systems enhance the efficacy of mRNA cancer vaccines.

• Supporting Evidence: Lipid nanoparticle (LNP)-mediated delivery systems have been shown to target lymph nodes, eliciting robust CD8+ T cell responses, which is crucial for effective anti-tumor immunity (Chen et al., 2022). Similarly, lipopolyplex (LPP)-formulated mRNA cancer vaccines encoding tandem neoantigens have demonstrated strong neoantigen-specific T cell responses and anti-tumor activity, addressing challenges related to delivery efficiency (Fan et al., 2024).
• Limitations: These are often preclinical or early-phase clinical findings, and optimization for human application and large-scale manufacturing is ongoing.
• Evidence Strength: Strong (for preclinical/early clinical efficacy of delivery systems).

Overall, the evidence strongly supports the potential of personalized cancer vaccines to elicit specific and durable anti-tumor immune responses, with ongoing advancements in vaccine platforms and delivery mechanisms.

Recent advancements in personalized cancer vaccines (PCVs) demonstrate significant progress in eliciting specific anti-tumor immune responses. A notable trend is the successful application of mRNA neoantigen vaccines in challenging cancers like pancreatic ductal adenocarcinoma (PDAC). Studies show that individualized mRNA-lipoplex vaccines, such as autogene cevumeran, can stimulate T cells in PDAC patients, leading to long-lived CD8+ T cell responses that persist for extended periods (e.g., 3.2-year median follow-up). These vaccines are designed to target mutation-derived neoantigens, a crucial step in overcoming the immune evasion mechanisms of such aggressive cancers.

Another emerging trend is the validation of PCVs in generating anti-tumor immunity against cancer driver mutations in renal cell carcinoma (RCC). These vaccines not only induce circulating immune responses but also demonstrate the ability to target a patient's tumor, leading to clinical activity. This indicates a move towards PCVs that can address the core genetic drivers of cancer, rather than just passenger mutations.

Furthermore, innovations in vaccine delivery systems are enhancing efficacy. Lipid nanoparticle (LNP) technology is being refined for targeted delivery of mRNA cancer vaccines to lymph nodes. This targeted approach is predicted to reduce systemic side effects and significantly increase the immune response by efficiently presenting neoantigens to immune cells. These developments collectively point towards more effective, durable, and precisely delivered personalized cancer vaccines.

Synthesis

Personalized cancer vaccines (PCVs) represent a paradigm shift in oncology, leveraging a patient's unique tumor neoantigens to elicit a targeted anti-tumor immune response. Recent clinical trials have provided compelling evidence for their potential. In pancreatic ductal adenocarcinoma (PDAC), a notoriously difficult-to-treat cancer, an individualized mRNA vaccine (autogene cevumeran) combined with checkpoint inhibition and chemotherapy induced substantial neoantigen-specific T cell responses, which were associated with delayed recurrence. Extended follow-up revealed these responses are durable, priming long-lived memory CD8+ T cells that persist for years. Similarly, a phase I trial in high-risk renal cell carcinoma (RCC) demonstrated that a neoantigen vaccine generated significant anti-tumor immunity. The field is rapidly advancing beyond initial proof-of-concept, focusing on optimizing vaccine platforms, delivery vehicles, and combination therapy strategies to broaden clinical benefit.

Methods and Materials

Vaccine Platforms: The dominant platform is mRNA, valued for its rapid, on-demand manufacturing and safety profile. Both uridine mRNA-lipoplex nanoparticles and circular RNA (circRNA) are being explored, with circRNA offering potential advantages in stability and expression persistence. Other approaches include peptide-based vaccines and whole-tumor-cell-derived vaccines, which utilize surgically removed tumor tissue or tumor extracellular vesicles (TEVs) as a source of patient-specific antigens.

Delivery Systems: Efficient delivery to antigen-presenting cells, particularly in lymph nodes, is critical. Lipid nanoparticles (LNPs) and lipopolyplexes (LPPs) are the leading delivery vehicles for mRNA vaccines, with novel formulations being developed to improve lymph node targeting and cellular uptake. Hydrogel matrices are also used to create depots for sustained release of vaccine components.

Neoantigen Identification: Computational toolkits like pVACtools are essential for the end-to-end process of identifying neoantigens from genomic data (point mutations, indels, gene fusions) and predicting their binding affinity to a patient's MHC molecules.

Applications

PCVs are primarily being investigated in the adjuvant setting to prevent postoperative recurrence in high-risk patients. Clinical trials have shown promise in solid tumors including:

• Pancreatic Ductal Adenocarcinoma (PDAC): An mRNA vaccine (autogene cevumeran) used post-surgery with atezolizumab and mFOLFIRINOX has shown delayed recurrence.
• Renal Cell Carcinoma (RCC): A neoantigen vaccine, with or without ipilimumab, has been tested in fully resected, high-risk RCC.
• Hepatocellular Carcinoma (HCC): Personalized neoantigen vaccines have been used to prevent postoperative recurrence in HCC patients with vascular invasion.

These vaccines are almost always used in combination with other immunotherapies, most commonly PD-1/PD-L1 checkpoint inhibitors, to overcome the immunosuppressive tumor microenvironment.

Limitations

Despite progress, significant challenges remain. The accuracy of computational neoantigen prediction is still suboptimal, and not all predicted neoantigens elicit a potent T cell response. The manufacturing process is complex, costly, and time-sensitive, which can be a barrier to widespread clinical adoption. Furthermore, the immunosuppressive tumor microenvironment can still render vaccine-induced T cells ineffective. Overcoming these hurdles requires better predictive biomarkers, more efficient manufacturing, and more potent combination therapies.

Update Triggers

This review would require an update upon the release of:

• Phase II/III clinical trial data confirming the efficacy of personalized vaccines in larger patient cohorts.
• Studies demonstrating successful application in additional tumor types, particularly those with low mutational burdens.
• Breakthroughs in neoantigen prediction algorithms that significantly improve the identification of immunogenic targets.
• Development of novel, more effective, or scalable delivery platforms (e.g., next-generation LNPs, oral vaccines).
• Head-to-head comparisons of different vaccine platforms (e.g., mRNA vs. peptide vs. viral vector) in a clinical setting.

Near-Term Research & Development

• Optimize Neoantigen Prediction: Improve computational pipelines (e.g., pVACtools) to more accurately identify and prioritize immunogenic neoantigens from tumor sequencing data. This includes better prediction of peptide processing, MHC binding, and T-cell receptor recognition, especially for tumors with low mutational burdens.
• Enhance Delivery Platforms: Develop and refine novel vaccine delivery systems beyond current lipid nanoparticles (LNPs). Promising areas include lipopolyplexes for stronger T-cell responses, endogenous LN-targeting LNPs to increase efficacy and reduce side effects, and exploring circular RNA (circRNA) for its potential stability and sustained expression advantages over linear mRNA.
• Combination Therapy Trials: Expand clinical trials combining personalized vaccines with other immunotherapies, particularly checkpoint inhibitors (e.g., anti-PD-L1). Phase I trials in PDAC and renal cell carcinoma show promise, indicating this synergy is crucial for overcoming tumor immunosuppression and achieving durable clinical responses.
• Adjuvant & Postoperative Settings: Focus research on the vaccine's role in preventing recurrence after surgery. Studies in hepatocellular carcinoma and PDAC suggest high value in the adjuvant setting for high-risk patients.

Validation & Benchmarking

• Standardized Immunogenicity Assays: Establish standardized benchmarks for assessing vaccine-induced immune responses. This must include quantifying the magnitude, quality (e.g., polyfunctionality), and durability of neoantigen-specific T-cell populations, particularly long-lived CD8+ T cells, as observed in recent PDAC trials.
• Correlative Studies: Systematically link vaccine-induced T-cell responses with clinical outcomes (e.g., recurrence-free survival, tumor regression). This requires deep immune monitoring of patient samples pre- and post-vaccination to identify biomarkers of response and resistance.
• Head-to-Head Platform Comparison: Conduct preclinical and eventually clinical studies comparing different vaccine platforms (mRNA, circRNA, peptide, viral vectors) using the same set of neoantigens to evaluate relative efficacy, safety, and manufacturing feasibility.

Key Datasets & Resources

• Integrated Clinical Trial Data: Public repositories of multi-omic tumor data (genomics, transcriptomics) linked with detailed clinical outcomes and longitudinal immune monitoring data from personalized vaccine trials. The TCGA is a foundational resource, but trial-specific datasets are critical.
• Neoantigen Immunogenicity Databases: A curated, large-scale database of validated immunogenic and non-immunogenic neoantigens across diverse HLA types and cancer indications to train and benchmark prediction algorithms.

Translational Barriers

• Manufacturing & Logistics: The on-demand, patient-specific manufacturing process is complex, costly, and time-sensitive. Streamlining this workflow from tumor biopsy to vaccine administration is a major logistical hurdle for widespread adoption.
• Tumor Heterogeneity & Evolution: Intra-tumoral heterogeneity means a vaccine targeting neoantigens from one part of a tumor may not address others. Tumors can also lose neoantigens under immune pressure (immunoediting), leading to escape and recurrence.
• Low Mutational Burden Tumors: Generating effective vaccines for cancers with few mutations (e.g., PDAC) is challenging. This requires highly accurate neoantigen prediction and potent vaccine platforms to induce a strong response from a limited target pool.

High-Value Experiments

• Adaptive Vaccine Trials: Design trials where the vaccine composition is updated based on the evolving neoantigen landscape of a patient's tumor, identified through serial liquid biopsies. This could counteract tumor immune evasion.
• 'Off-the-Shelf' Shared Neoantigen Vaccines: For tumors with recurrent driver mutations (e.g., KRAS), develop and test partially personalized or 'off-the-shelf' vaccines targeting shared neoantigens to reduce manufacturing complexity and cost.
• Novel Adjuvant & Delivery System Testing: Preclinically test the integration of novel adjuvants or delivery mechanisms, such as photothermal activation or tumor extracellular vesicles, with established mRNA vaccine backbones to determine if they can further enhance the magnitude and breadth of the anti-tumor T-cell response.